Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.
Clinical Trials Arena on MSN1d
Amgen’s gMG therapy cuts disease symptoms at one-year markAmgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of gMG patients after 52 weeks in a Phase III ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published.
NEW YORK, Feb. 18, 2025 /PRNewswire/ -- A newly identified part of a brain circuit mixes sensory information, memories, and emotions to tell whether things are familiar or new, and important or ...
After hours: March 13 at 7:59:56 PM EDT Loading Chart for ACHR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback